Pfizer Europe MA EEIG — China drug registrations and re-registration deadlines
50 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2026-10-26.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20220040 | LORBRENA 洛拉替尼片 | 2027-04-26 | 2026-10-26 |
| 国药准字HJ20220041 | LORBRENA 洛拉替尼片 | 2027-04-26 | 2026-10-26 |
| 国药准字HJ20171137 | SUTENT 苹果酸舒尼替尼胶囊 | 2027-07-28 | 2027-01-28 |
| 国药准字HJ20171138 | SUTENT 苹果酸舒尼替尼胶囊 | 2027-07-28 | 2027-01-28 |
| 国药准字HJ20171139 | SUTENT 苹果酸舒尼替尼胶囊 | 2027-07-28 | 2027-01-28 |
| 国药准字HJ20171140 | SUTENT 苹果酸舒尼替尼胶囊 | 2027-07-28 | 2027-01-28 |
| 国药准字HJ20171141 | SUTENT 苹果酸舒尼替尼胶囊 | 2027-07-28 | 2027-01-28 |
| 国药准字HJ20171142 | SUTENT 苹果酸舒尼替尼胶囊 | 2027-07-28 | 2027-01-28 |
| 国药准字HJ20171143 | SUTENT 苹果酸舒尼替尼胶囊 | 2027-07-28 | 2027-01-28 |
| 国药准字HJ20171144 | SUTENT 苹果酸舒尼替尼胶囊 | 2027-07-28 | 2027-01-28 |
| 国药准字HJ20181102 | Vfend 注射用伏立康唑 | 2027-10-24 | 2027-04-24 |
| 国药准字SJ20150003 | Xyntha 注射用重组人凝血因子Ⅷ | 2027-11-14 | 2027-05-14 |
| 国药准字SJ20150004 | Xyntha 注射用重组人凝血因子Ⅷ | 2027-11-14 | 2027-05-14 |
| 国药准字SJ20150005 | Xyntha 注射用重组人凝血因子Ⅷ | 2027-11-14 | 2027-05-14 |
| 国药准字SJ20150006 | Xyntha 注射用重组人凝血因子Ⅷ | 2027-11-14 | 2027-05-14 |
| 国药准字SJ20120053 | BeneFIX 注射用重组人凝血因子Ⅸ | 2027-12-21 | 2027-06-21 |
| 国药准字SJ20120054 | BeneFIX 注射用重组人凝血因子Ⅸ | 2027-12-21 | 2027-06-21 |
| 国药准字SJ20120055 | BeneFIX 注射用重组人凝血因子Ⅸ | 2027-12-21 | 2027-06-21 |
| 国药准字SJ20120056 | BeneFIX 注射用重组人凝血因子Ⅸ | 2027-12-21 | 2027-06-21 |
| 国药准字HJ20150129 | Vfend 伏立康唑干混悬剂 | 2028-05-28 | 2027-11-28 |
| 国药准字HJ20180040 | IBRANCE 哌柏西利胶囊 | 2028-05-28 | 2027-11-28 |
| 国药准字HJ20180041 | IBRANCE 哌柏西利胶囊 | 2028-05-28 | 2027-11-28 |
| 国药准字HJ20180042 | IBRANCE 哌柏西利胶囊 | 2028-05-28 | 2027-11-28 |
| 国药准字HJ20130697 | Sirolimus Tablets 西罗莫司片 | 2028-06-13 | 2027-12-13 |
| 国药准字HJ20130698 | Sirolimus Tablets 西罗莫司片 | 2028-06-13 | 2027-12-13 |
| 国药准字HJ20171221 | Champix 酒石酸伐尼克兰片 | 2028-08-09 | 2028-02-09 |
| 国药准字HJ20171222 | Champix 酒石酸伐尼克兰片 | 2028-08-09 | 2028-02-09 |
| 国药准字HJ20171223 | Champix 酒石酸伐尼克兰片 | 2028-08-09 | 2028-02-09 |
| 国药准字HJ20150051 | Vfend 伏立康唑片 | 2028-10-09 | 2028-04-09 |
| 国药准字HJ20150052 | Vfend 伏立康唑片 | 2028-10-09 | 2028-04-09 |
| 国药准字HJ20190036 | Vizimpro 达可替尼片 | 2029-02-27 | 2028-08-27 |
| 国药准字HJ20190037 | Vizimpro 达可替尼片 | 2029-02-27 | 2028-08-27 |
| 国药准字SJ20170048 | Enbrel 依那西普注射液 | 2029-06-05 | 2028-12-05 |
| 国药准字SJ20170049 | Enbrel 依那西普注射液 | 2029-06-05 | 2028-12-05 |
| 国药准字HJ20200001 | Vyndaqel 氯苯唑酸葡胺软胶囊 | 2029-06-27 | 2028-12-27 |
| 国药准字HJ20150219 | Inlyta 阿昔替尼片 | 2029-08-18 | 2029-02-18 |
| 国药准字HJ20150220 | Inlyta 阿昔替尼片 | 2029-08-18 | 2029-02-18 |
| 国药准字HJ20150221 | Inlyta 阿昔替尼片 | 2029-08-18 | 2029-02-18 |
| 国药准字HJ20150222 | Inlyta 阿昔替尼片 | 2029-08-18 | 2029-02-18 |
| 国药准字HJ20240122 | TALZENNA 甲苯磺酸他拉唑帕利胶囊 | 2029-10-28 | 2029-04-28 |
| 国药准字HJ20240123 | TALZENNA 甲苯磺酸他拉唑帕利胶囊 | 2029-10-28 | 2029-04-28 |
| 国药准字HJ20240124 | TALZENNA 甲苯磺酸他拉唑帕利胶囊 | 2029-10-28 | 2029-04-28 |
| 国药准字HJ20200041 | Vyndamax 氯苯唑酸软胶囊 | 2030-03-24 | 2029-09-24 |
| 国药准字HJ20250078 | Aztreonam and Avibactam Sodium for Injection 注射用氨曲南阿维巴坦钠 | 2030-06-23 | 2029-12-23 |
| 国药准字SJ20160042 | Prevenar 13 13价肺炎球菌多糖结合疫苗 | 2030-12-21 | 2030-06-21 |
| 国药准字HJ20160471 | Tygacil 注射用替加环素 | 2031-01-04 | 2030-07-04 |
| 国药准字HJ20160472 | Tygacil 注射用替加环素 | 2031-01-04 | 2030-07-04 |
| 国药准字HJ20181078 | Xeljanz 枸橼酸托法替布片 | 2031-05-05 | 2030-11-05 |
| 国药准字HJ20181079 | Xeljanz 枸橼酸托法替布片 | 2031-05-05 | 2030-11-05 |
| 国药准字HJ20181080 | Xeljanz 枸橼酸托法替布片 | 2031-05-05 | 2030-11-05 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.